NSE: undefined BSE: undefined
₹-
(-%)
Fri, 01 May 2026, 03:01 am
Analysis
dividend
- Unable to evaluate Earum Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Earum Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Earum Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Earum Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Earum Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 3.4x debt.
- Earum Pharmaceuticals's cash and other short term assets cover its long term commitments.
- Operating cash flow is negative therefore debt is not well covered.
- Interest payments on debt are not well covered by earnings (EBIT is 2.8x annual interest expense, ideally 3x coverage).
- Earum Pharmaceuticals's level of debt (60.6%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- Bhumishth's remuneration is lower than average for companies of similar size in India.
- The average tenure for the Earum Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
- The average tenure for the Earum Pharmaceuticals management team is less than 2 years, this suggests a new team.
misc
- Earum Pharmaceuticals is not covered by any analysts.
- Earum Pharmaceuticals's last earnings update was 225 days ago.
- Earum Pharmaceuticals has significant price volatility in the past 3 months.
past
- Earum Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
- Earum Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Earum Pharmaceuticals used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Earum Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Earum Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Earum Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- BSE:542724 is up 12.6% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:542724 is up 12.6% outperforming the market in India which returned 8% over the past month.
- Earum Pharmaceuticals is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Earum Pharmaceuticals is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Earum Pharmaceuticals is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800